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ABSTRACT For another year, high-quality research studies from around the world transformed the annual
ERS International Congress into a vivid platform to discuss trending research topics, to produce new research
questions and to further push the boundaries of respiratory medicine and science. This article reviews only
some of the high-quality research studies on asthma, chronic obstructive pulmonary disease (COPD),
bronchiectasis and chronic cough that were presented during the congress through the Airway Diseases
Assembly (ERS Assembly 5) and places them into the context of current knowledge and research challenges.
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Asthma is one of the most common inflammatory diseases globally yet it has been defined by quite broad
definitions, such as breathlessness and wheezing, that are associated with variable airflow obstruction and
inflammation within the lungs [1]. It becomes increasingly clear that asthma shows a high degree of
heterogeneity [2]. Nevertheless, treatment strategies for asthma are largely non-specific, commonly
including glucocorticosteroids and bronchodilators. Although most patients respond well to this therapy, a
remaining group of asthmatic patients does not respond to the available treatments, accounting for a great
part of the economic and health burden of the disease [3]. Furthermore, diagnosis and/or treatment of
unresponsiveness to therapy or severity of asthma often does not take into account the various underlying
pathological processes, mostly due to the limited information available on how to correlate clinical
phenotypes to biological endotypes [4, 5].
In a study by BIGLER et al. [6], nearly 1700 genes were found to be differently expressed in blood samples
from severe asthma patients compared to non-asthmatic individuals. In asthmatic patients, pathway
analysis showed specific immune cell patterns such as upregulation of genes associated with eosinophils
and neutrophils and decreased expression of genes involved in blood-lymphocyte development and
haematopoietic progenitor cells. Interestingly, cluster analysis showed subgroups within the severe asthma
group who differed in their response to treatment with corticosteroids [6]. At this year’s congress, AFFLECK
et al. [7] presented a sequential study comparing blood transcriptomic profiles of adults and children from
the U-BIOPRED study with the aim of investigating if a similar dysregulation would be seen in children
with asthma. They reported that while the school-aged children showed some differentially expressed gene
(DEG) overlap with the adults they were distinct in many pathways, indicating that childhood and adult
asthma may be mechanistically different [7].
Indeed, age of disease onset is a significant discriminating factor between different asthma phenotypes and
an important factor in severe asthma [8]. In a recent study by HEKKING et al. [9], gene set variation
analysis was used to identify gene profiles associated with adult-onset severe asthma. This study compared
adult-onset with childhood-onset severe asthmatics from the U-BIOPRED cohort using samples from
nasal and bronchial brushings, induced sputum and endobronchial biopsies. Gene signatures related to
airway inflammation characterised by eosinophils, mast cells and innate lymphocyte cells (ILCs) of Group
3 (ILC3s) were enriched in adult-onset severe asthma. The study by HEKKING et al. [9] also showed that in
childhood-onset severe asthma, signatures associated with lung damage were more pronounced. This is
interesting as it has been proposed that impaired epithelial damage repair mechanisms are important
drivers in asthma development [10]; however, very little is known regarding the natural origin of asthma
development. Furthermore, PAVLIDIS et al. [11] presented a follow-up study from the U-BIOPRED group at
this year’s European Respiratory Society (ERS) Congress which aimed to explore the enrichment of ILC1,
ILC2 and ILC3 activation signatures in asthmatic transcriptomic samples. From this study, they conclude
that a neutrophilic severe asthma phenotype was characterised by Group 1 ILC activation, associated with
inflammasome, interferon-γ (IFN-γ) and tumour necrosis factor (TNF), which may reflect an
antimicrobial response and contribute to chronic inflammation and remodelling in severe asthma.
Respiratory syncytial virus (RSV) and rhinovirus infections are major causes of bronchiolitis and
pneumonia and are strongly associated with asthma exacerbations [12, 13]. Wheezing in response to viral
infections correlates to asthma development in children [14, 15] and, while the majority children who
wheeze upon viral infection recover without any enduring effects, a proportion of children with wheeze
will develop asthma later in life [16, 17]. Despite strong evidence from longitudinal studies, it is not
known how viral infections during early childhood are connected to the development of asthma [16, 17].
However, two concepts have emerged to explain why asthmatic patients are more sensitive to viral
infections: 1) an exaggerated Type 2 T-helper cell (Th2) immune response towards viruses with increased
levels of interleukin (IL)-4, IL-5 and IL-13 cytokines, and 2) a deficient anti-viral response primarily
explained by impaired production of Type I and Type III IFNs [12]. Several in vivo and in vitro studies in
human airway cells and murine models have shown a deficiency in IFN production in response to viral
infection, a trend which is especially pronounced in severe asthmatic disease (see EDWARDS et al. [18]).
Furthermore, the risk of developing asthma is increased with frequent viral-induced bronchiolitic episodes
in combination with allergic sensitisation to airborne allergens [19]. RUBNER et al. [20] showed in a recent
study that the age of sensitisation (age <1 year) and rhinovirus infection (but not RSV) was important for
asthma development by adolescence. It has furthermore been reported that rhinovirus causes amplified
release of double stranded DNA in individuals with asthma undergoing rhinovirus-induced asthma
exacerbations and that the levels correlated with both symptom severity during exacerbation and
rhinovirus-induced release of Type 2 cytokines [21]. In a study by DANOV et al. [22], which was presented
at this year’s ERS Congress, the impact of an asthmatic background on the anti-viral and
pro-inflammatory immune response was investigated in precision-cut lung slices (PCLS) of house dust
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mite (HDM)-sensitised mice. The authors showed that the HDM-induced allergic inflammation was
maintained ex vivo in the PCLS and led to a reduced immune response to rhinovirus infection, as shown
by decreased secretion of IFN-γ, IFN-γ-inducible protein 10 (IP-10) and IL-17A in response to HRV1B
infection. Interestingly, Th2 cytokine IL-4 was further induced in rhinovirus-infected PCLS of
HDM-sensitised mice.
A compelling amount of data now points towards a miscommunication between the innate and adaptive
immune response towards viruses in asthmatic patients. Recent data has shown that, upon damage,
epithelial cells release the alarmin IL-33 and data from genome-wide association studies has implicated
IL-33 in the pathobiology of allergic diseases [23, 24]. At the ERS Congress this year there were several
abstracts related to the role of IL-33 in asthma pathology (see RAVANETTI et al. [25], HACCURIA et al. [26]
and PERKINS et al. [27]). Higher levels of IL-33 have been found in subjects with severe asthma when
compared with healthy controls [28]. The increased levels of IL-33 might be important since it can
promote both innate and adaptive immune responses and can influence the cross-talk between these two
arms of immune defense [29, 30]. In line with this, LYNCH et al. [31, 32] reported that IL-33 can suppress
innate anti-viral immune defense which in turn results in increased viral burden, airway smooth muscle
hyperplasia and Th2 inflammation. A sequential study presented by UPHAM et al. [33] was aimed at
examining the mechanisms involved and especially the two chains of the IL-33 receptor (IL-1 receptor like
1 (IL1RL, also known as ST2) and IL-1 receptor accessory protein (IL1RAP)). Peripheral blood
mononuclear cells (PBMC) obtained from mild/moderate asthmatics and healthy donors were exposed to
IL-33 and activated with rhinovirus. In asthmatic patients, rhinovirus alone or in combination with IL-33
induced significantly greater upregulation of ST2 mRNA expression than in healthy participants but had
no effect on IL1RAP expression. The results were confirmed using flow cytometry and the increase was
due to enhanced ST2 expression on ILC2s and T-lymphocytes. These findings suggest there is
dysregulation of ST2 in asthma and provide a mechanism by which rhinovirus infections might exacerbate
Type 2 inflammation.
Taken altogether, asthma is a very heterogeneous disease with specific gene patterns that, with increasing
knowledge, will enable a more thorough stratification of asthmatic phenotypes. It is now vital that these
phenotypes be linked to biological endotypes, where studies of the effects of biological treatments will be
of great importance. The aforementioned studies further stress the notion that the complex interplay
between viral infection and allergen exposure is important for the onset and progression of asthmatic
disease. Difficult-to-treat patients that are unresponsive to conventional therapy would most likely benefit
greatly from a thorough phenotyping and endotyping of their pathophysiology, with the ultimate goal of
administering more specialised and personalised medication.
Chronic obstructive pulmonary disease
Pharmacological treatment of chronic obstructive pulmonary disease (COPD) aims to reduce symptoms,
frequency and severity of exacerbations, to improve exercise tolerance and health status, and also to delay
disease progression and death [34]. While there is still no conclusive evidence from clinical trials
indicating that any of the existing COPD medications modify disease progression, there is
fast-accumulating evidence on how to optimise symptom control and exacerbation prevention.
First, several trials assessing triple therapy, inclusive of a long-acting β-2 agonist, a long-acting
antimuscarinic and an inhaled corticosteroid in a single device were presented. The FULFIL trial
compared the triple combination of fluticasone furoate, umeclidinium and vilanterol against the
combination of budesonide and formoterol in a 24-week randomised trial involving 1810 patients. It
demonstrated the superiority of the triple combination with regards to spirometry, frequency of
exacerbations, frequency of pneumonias, quality of life (QoL) and time to clinically important
deterioration (CID, a composite measure of lung function, health status and exacerbation). The median
time to first CID was 169 days for the triple combination versus 31 days for the long-acting β-agonist
(LABA)/inhaled corticosteroid (ICS) combination [35, 36]. However, this study can be criticised for
comparing a triple combination versus an ICS/LABA combination, rather than a single dose triple
combination versus separate devices, which would have been more informative. Such an intervention was
evaluated by the TRINITY trial [37] which compared the fixed triple combination of beclometasone
dipropionate, formoterol fumarate and glycopyrronium bromide against the open triple combination of
beclometasone dipropionate and formoterol fumarate plus tiotropium, or tiotropium alone, in a 52-week
randomised controlled trial involving 2691 patients. The fixed triple combination was found to be superior
to the long-acting muscarinic antagonist (LAMA) and to be non-inferior to the open triple combination
with regards to frequency of moderate-to-severe exacerbations, time to first CID, spirometry and adverse
effects [38]. Use of triple combination therapy is currently only recommended for Global Initiative for
Chronic Obstructive Lung Disease (GOLD) Group D patients under current GOLD guidelines [34].
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However, a post hoc analysis of the TRINITY and TRILOGY [39] trials this year has assessed the impact of
fixed triple combination therapy versus LABA/ICS or LAMA therapy in Group B patients and found a
significant decrease in the frequency of exacerbations [40].
Dual bronchodilation has also received a lot of attention this year. The FLAME trial, a 52-week trial
involving 3362 patients with COPD and a history of at least one moderate or severe exacerbation during
the preceding year, compared a fixed combination of indacaterol/glycopyrronium (LABA/LAMA) against
salmeterol/fluticasone (LABA/ICS) and demonstrated the superiority of the LABA/LAMA combination
versus the LABA/ICS combination with regards to exacerbations, lung function and QoL [41]. Several
post-hoc analyses from the FLAME trial were presented this year, evaluating more domains and
confirming the superiority of the LABA/LAMA combination. The number needed to treat (NNT) to avoid
a moderate or severe COPD exacerbation (per year) was estimated to be 4.76 patients with dual
bronchodilation. In addition, the NNT to keep a patient with at least one exacerbation in the preceding
year free of exacerbations was 15 [42]. Indacaterol/glycopyrronium was also shown to be useful in
reducing the risk of CID, defined as a decrease of 100 mL in forced expiratory volume in 1 s (FEV1) or an
increase of four points on the St George’s Respiratory Questionnaire (SGRQ). Indacaterol/glycopyrronium
reduced the risk of first and sustained CID by approximately 30% versus salmeterol/fluticasone, as
presented by ANZUETO et al. [43]. Further analyses confirmed the safety of dual bronchodilation as it was
associated with fewer respiratory-related adverse events of special interest, including but not limited to
pneumonia, compared with salmeterol/fluticasone [44]. The cost effectiveness of indacaterol/
glycopyrronium compared to treatment with salmeterol/fluticasone was also assessed in a real-life context,
in the ARCTIC Swedish cohort study of 18,586 subjects over 3 years. Dual bronchodilation was associated
with lower total direct costs (a saving of 732 euro per patient) and better outcomes (0.008 quality-adjusted
life-years and 0.005 life-years gained).
The ACLIFORM and AUGMENT trials compared another dual bronchodilator (aclidinium/formoterol)
against its monocomponents or a placebo, in 3394 maintenance treatment naïve patients with moderate or
severe COPD over a 24-week period and in a double-blinded fashion. Pooled studies from these trials have
demonstrated the superiority of aclidinium/formoterol versus its monocomponents or a placebo with
regards to symptoms, QoL, frequency of exacerbations and use of relief medications [45, 46]. ACTIVATE,
an 8-week trial of 267 patients also found that aclidinium/formoterol significantly improved physical
activity compared to a placebo at 4 and 8 weeks [47].
The use of a fixed-dose dual bronchodilator was also evaluated in 4117 COPD patients under real-life
conditions in the DACCORD study [48]. Patients were recruited following a change in their maintenance
treatment by their clinicians (as indicated by a non-interventional study) and the exacerbation frequency
of patients who received a LABA/LAMA combination versus other treatments was compared [49]. Dual
bronchodilation was correlated with significantly fewer exacerbations amongst those patients who had at
least one exacerbation in the 6 months preceding recruitment.
Finally, in an interesting animal study, GOSSET et al. [50] assessed the effect of prophylactic administration
of flagellin, a toll-like receptor 5 (TLR5) agonist, in mice with COPD. Mice treated with flagellin were
found to have significantly lower bacterial load in bronchoalveolar lavage (BAL), suggesting a potential
protective effect of flagellin against bacterial infection or colonisation. This opens a new therapeutic line in
terms of the stimulation of the innate immune response to prevent COPD exacerbations.
Overall, data are fast accumulating which support the effectiveness of bronchodilators, inhaled steroids and
combination therapies, which clearly improve the health status and QoL of patients while decreasing the
frequency of exacerbations. Unfortunately, there are still significant challenges ahead as none of the
available treatments can halt or delay disease progression or prolong survival. In addition, our expanding
understanding of COPD heterogeneity and clinical phenotypes has only now started to be translated into
the development of better, targeted treatments.
Novel monoclonal antibodies in asthma and COPD
Asthma and COPD are common chronic inflammatory airways diseases that affect an estimated 700
million people worldwide [51, 52]. Despite taking high dose inhaled and often daily oral steroid
treatments, approximately 5–10% of patients with asthma have severe asthma [53] and between 30–40% of
patients with COPD have recurrent moderate to severe exacerbations on inhaled triple therapy [54], even if
there is an increasing body of evidence for positive results in patients’ QoL. This results in a high burden
of disease on QoL and employment, as well as pressure on healthcare services. Over the last 20 years, there
has been a focus on treating uncontrolled patients by understanding the underlying pathological
mechanisms which lead to such complex heterogeneous airways diseases. Mechanistic studies have
highlighted the role of Type 2 inflammatory cytokines (IL-4, IL-5, IL-9 and IL-13) and airway eosinophils
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as important biomarkers to target in asthma; however, only recently has evidence emerged showing the
limited benefits of such a targeted strategy in COPD [55]. A potential limitation in studies targeting IL-5
or eosinophils is that such drugs largely benefit patients who demonstrate an eosinophilic phenotype,
hence excluding a large proportion of subjects. However, novel data has shown the importance of
inflammatory cytokines secreted from the airway epithelium in orchestrating and activating Type 2
inflammation [56] and Group 2 ILCs (ILC2s) [57]. These are collectively known as the epithelial
“alarmins” and currently include IL-33, IL-25 and thymic stromal lymphopoietin (TSLP). The latter has
emerged as an important target for asthma, irrespective of allergic or eosinophilic status. Here we focus on
data presented at the ERS International Congress 2017 for tezepelumab (in patients with uncontrolled
asthma) and mepolizumab (for eosinophilic COPD), as they represent an advancement in both our
current understanding and our future treatment options.
TSLP is produced from the airway epithelium in response to a wide variety to external stimuli, such
allergens and viruses, and has the ability to act as an “epithelial alarmin” by activating Type 2
inflammation via activation of dendritic cells, ILC2s, T-cells and B-cells, resulting in an increase in airway
inflammatory cytokines, particularly IL-4, IL-5 and IL-13. An earlier proof of concept study showed the
efficacy of tezepelumab in reducing the early and late asthmatic responses in an allergen challenge model,
with profound reductions in both serum and sputum eosinophils [56]. However, most asthma
exacerbations occur due to viral exacerbations and all patients in the allergen challenge model were steroid
naïve and well controlled. As such, the rationale for this larger multicentre, placebo-controlled,
double-blind follow up study was to test the efficacy of tezepelumab in a much broader population of
uncontrolled moderate to severe asthma patients unselected for serum eosinophils [58]. Over a 52-week
period, tezepelumab (70 mg or 210 mg every 4 weeks, or 210 mg every 2 weeks) reduced exacerbation rates
by 61%, 71% and 66% more than a placebo, respectively, and, most importantly, this improvement was
seen irrespective of blood eosinophil count at baseline. There were significant improvements in
pre-bronchodilator FEV1, asthma control and reductions in exhaled nitric oxide fraction (FeNO) and serum
IgE. This suggests that the rationale of inhibiting the inflammatory cascade higher up the pathway is
effective at augmenting a wider range of Type 2 inflammatory mediators irrespective of allergic or
eosinophil status. These findings make the results of this study different to those observed previously
(targeting IL-5 or its receptor subunit only). The only caveats to this study were that the majority of
patients were recruited from Eastern Europe and Ukraine, 90% were Caucasian and there was a large
placebo effect. Further Phase 3 studies in different healthcare settings and with broader ranges of
ethnicities would add value to these initial results.
Although the targeting of eosinophils has most often been associated with treating asthma, there have
been important observations to suggest a role in COPD. The ECLIPSE study showed that nearly 40% of
patients had persistently raised serum eosinophils (⩾2%), which was associated with an increased risk of
exacerbations, but were highly responsive to corticosteroids [59]. However, the side-effects profile,
particularly the increased risk of pneumonia, has more recently led to a renewed emphasis on steroid
reduction and alternative treatment strategies. The rationale to this study was rooted in observing an
association between lower exacerbation rates than placebo in two mepolizumab in severe asthma studies
with some features of COPD (the MENSA and DREAM studies). The objective of this study was to
evaluate the efficacy and safety of subcutaneous mepolizumab, as compared with placebo, as an
additional treatment to inhaled triple therapy in those COPD patients with an eosinophilic phenotype
and a history of moderate or severe exacerbations [60]. An eosinophilic phenotype was defined as
⩾150 cells·mm−3 at screening or ⩾300 cells·mm−3 in the previous year and moderate exacerbations were
defined as ⩾2 episodes requiring steroids±antibiotics (and as severe if leading to hospitalisation). The
data presented demonstrated an 18% reduction in combined moderate and severe exacerbations only in
those patients defined as having an eosinophilic phenotype, with the greatest effect seen in those with
the highest eosinophil counts. However, no difference was found in hospitalisations, emergency
department visits, FEV1 or QoL endpoints, nor is there any data currently available for the possibility of
steroid dose reduction as has been seen in asthma. The implication of these results is to potentially use
serum eosinophils as a biomarker to identify those most likely to benefit from such immune therapy.
However, this needs to be balanced with the fact that there was a large improvement in exacerbations in
the placebo group likely related to improved adherence during the clinical trial. This is not unusual for
most trials in COPD and asthma but raises the question of the need for such expensive treatment in a
resource-stretched healthcare system.
Overall, studies involving monoclonal antibodies in patients with asthma and now COPD have
improved our understanding of airway pathobiology; however, applicability, long term safety and cost
effectiveness for a large (and broader) population will ultimately dictate eligibility and access to such
treatments.
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Non-cystic fibrosis bronchiectasis
Bronchiectasis is a disease accompanied by irreversible enlargement of the airways and is characterised by
ineffective mucociliary clearance and excessive inflammation. The inflammation is not just excessive it is
also ineffective, as it causes airway destruction and distortion which leads to ineffective mucus clearance.
Ineffective mucus clearance in turn leads to bacterial colonisation, which itself enhances inflammation-the
so called “vicious cycle” of bronchiectasis. Pseudomonas bacteria frequently colonise the airways of
patients with bronchiectasis and this is associated with exacerbations and disease severity. This year,
CHALMERS et al. [61] further evaluated the impact of Pseudomonas colonisation on the outcomes of
bronchiectasis using data from the Facilitating Research Into Existing National Datasets (FRIENDS)
cohort, a historical dataset integrating national registries of bronchiectasis from the past decade with the
intention of giving a clear picture of bronchiectasis management and outcomes and including 2596
patients with high-resolution computed tomography (HRCT) confirmed bronchiectasis. Researchers found
Pseudomonas colonisation to be associated with worse symptoms, radiologic severity and more frequent
exacerbations (median: three per year). Importantly, they also demonstrated that colonised patients were at
twice as high a risk of death.
Furthermore, SMITH et al. [62] identified a novel biomarker of disease severity starting from the
observation that most patients with bronchiectasis are women. More specifically, they found high levels of
pregnancy zone protein (PZP, an oestrogen-regulated antiprotease) in the sputum of patients with
bronchiectasis and explored its prognostic value in 80 patients. PZP was strongly correlated with
bronchiectasis severity index, SGRQ, level of breathlessness and Pseudomonas infection.
At the ERS Congress, several high quality studies focused on bronchiectasis management, which is
complex and needs to cover the management of both acute exacerbations and stable disease (including
exacerbation prevention). During stable disease, control of microbial load decreases inflammation and
mucus production and delays subsequent exacerbations. Inhaled antibiotic therapy includes colistin and
gentamycin, and there are ongoing trials with ciprofloxacin and levofloxacin. Indeed, FOEHLICH et al. [63]
reported in Milan on a post-hoc analysis of two 48-week trials involving 148 participants colonised by
Pseudomonas, which demonstrated that long-term, intermittent use of ARD-3150, a combination of
liposome-encapsulated and free ciprofloxacin, significantly decreased the frequency of pulmonary
exacerbation in bronchiectasis patients, regardless of the Pseudomonas’ susceptibility to ciprofloxacin.
Macrolide antibiotics also possess potent anti-inflammatory effects [64]. In cases of rhinovirus infection,
macrolides increase the release of IFN and decrease viral load [65]. Many multicentre trials have
investigated macrolide use in bronchiectasis and, while they significantly decrease exacerbation rate and
increase the time to first exacerbation, they do not influence FEV1. There is however an improvement in
QoL based on the SGRQ [66–70]. Macrolides suppress systemic inflammation and C-reactive protein
(CRP) decreases along with sputum and peripheral neutrophil counts. If exacerbation rate is more than
three per year then the use of macrolides is beneficial. In accordance with these results MERTSCH et al.
[71] found that 33% of patients in a German cohort were on azithromycin maintenance therapy, while
DHAR et al. [72] showed that 55.1% of patients who were on antibiotic treatment in India received
low-dose macrolides (31% with azithromycin).
The role of long-term administration of antibiotics in patients with bronchiectasis and frequent
exacerbation is indisputable. However, further studies are required to compare the efficacy and safety of
different treatment regimes (different antibiotics, route of administration and frequency etc.). Importantly,
bronchial hygiene and mucolytic treatments are effective and safer and need to be prioritised.
Chronic cough
Cough is the primary reason for patients to visit a physician [73] and yet it remains an unmet medical
need. Chronic cough, which can occur as a result of respiratory disease but can also be idiopathic in
nature [74] can severely lower the QoL of sufferers [75]. In the year preceding March 2013, over $156
million was spent in the UK on cough medications [76] despite the fact that they have been shown to be
ineffective. Therefore, there is an urgent requirement for new, safe and effective therapies, and the clinical
problem of cough was highlighted at the ERS Congress where there was a “meet the expert” seminar on
the topic. At this event, Professor Alyn Morice talked clinicians through the underlying mechanisms,
diagnosis and treatment of patients with refractory chronic cough.
Cough is a reflex event triggered following activation of airway sensory nerves housed within the vagus
nerve [77]. Sensory nerve terminals are distributed throughout the airways and express a number of ion
channels and receptors that could represent novel targets for treatment. To date, the only ion channel
antagonist that has shown efficacy in refractory chronic cough is P2X2/3 antagonist MK-7264 (formerly
AF-219), which significantly inhibited daytime objective cough frequency by 75%. This indicates that the
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endogenous ligand of this ion channel, ATP, is likely to play a role in refractory chronic cough [78]. Two
clinical studies highlighted at the ERS Congress showed further results with this compound. SMITH et al.
[79] presented the results of a double-site, 12-week parallel group study with MK-7264 in patients with
refractory chronic cough. A total of 253 patients were given a placebo or the P2X3 antagonist MK-7264
(one of three doses: 7.5 mg, 20 mg or 50 mg, all of which were lower than that used in the original study
where most patients experienced dysgeusia) and awake cough frequency and 24-h cough frequency were
assessed. Despite a large placebo effect, both of these end points were significantly reduced following
treatment with the 50 mg dose of MK-7264, indicating that this compound is efficacious at more
well-tolerated doses. MORICE et al. [80] also presented a study utilising this compound. Their study looked
at evoked tussive responses to ATP, citric acid, capsaicin or distilled water (fog) following treatment with
MK-7264 or a placebo in healthy controls and patients with refractory chronic cough. All tussive
challenges evoked a cough response in chronic cough patients but only cough responses to ATP and fog
were inhibited with the antagonist, indicating successful target engagement by the compound. Another
study indicated that activation of airway sensory nerves by hypo-osmolar solutions such as distilled water
was through activation of the ion channels TRPV4 and TRPM3, which release ATP to activate P2X3 [81].
Other notable studies investigated other receptors which may be involved in the cough response.
DICPINIGATIS et al. [82] looked at the effect of the α7 nicotinic receptor in guinea pig cough. The authors
observed that in healthy non-smoking individuals, e-cigarettes containing nicotine had a marked
antitussive effect and therefore hypothesised that nicotine could inhibit cough. In a guinea pig model, it
was indicated that nicotine and selective agonists of the α7 nicotinic receptor inhibited cough induced by
citric acid and therefore the antitussive effects of e-cigarettes were likely to be through the α7 nicotinic
receptor. A further study by WORTLEY et al. [83] highlighted the inhibitory effects of agonists of the EP2
and EP4 receptors on TRPV1 induced responses. EP2 and EP4 are receptors for the inflammatory
mediator prostaglandin E2, which has been shown to have a variety of beneficial and detrimental effects in
the airways. EP3 evokes cough and EP2 and EP4 have protective bronchodilator and anti-inflammatory
effects; however, these inhibitory effects are lost following cigarette smoke exposure indicating that
prostanoids could play a role in cough in diseases such as COPD.
Overall, the novel studies showcased at the ERS Congress indicate that the search for an effective treatment
for the troublesome problem of chronic refractory cough is underway. Perhaps the most promising is the
P2X3 antagonist MK-7264, which has now shown efficacy in two clinical trials along with successful target
engagement. In addition, further pre-clinical studies have highlighted other potential targets for the
treatment of refractory chronic cough.
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